STOCK TITAN

ContraFect Corporation - $CFRX STOCK NEWS

Welcome to our dedicated page for ContraFect Corporation news (Ticker: $CFRX), a resource for investors and traders seeking the latest updates and insights on ContraFect Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ContraFect Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ContraFect Corporation's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.44%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.79%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.16%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
ContraFect Corporation

Nasdaq:CFRX

CFRX Rankings

CFRX Stock Data

535.24k
10.69M
0.65%
6.13%
2.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Yonkers

About CFRX

we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba